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Abstract—This paper proposes a parameterized Support
Vector Machine (ParaSVM) approach for modeling the Drug
Concentration to Time (DCT) curves. It combines the merits
of Support Vector Machine (SVM) algorithm that considers
various patient features and an analytical model that approxi-
mates the predicted DCT points and enables curve calibrations
using occasional real Therapeutic Drug Monitoring (TDM)
measurements. The RANSAC algorithm is applied to construct
the parameter library for the relevant basis functions. We show
an example of using ParaSVM to build DCT curves and then
calibrate them by TDM measurements on imatinib case study.
I. INTRODUCTION
Drug administration is one of the most common clinical
routines in hospitals. Once a new patient is admitted, an
initial drug dose and intake interval must be prescribed,
which we call an a priori drug dose adaptation. In current
clinical practice, the dose and its intake interval are chosen
on the basis of averaging the population values and doctors’
medical experience. This approach does not guarantee a
proper prescription to a patient with condition different from
those patients based on whose samples the library datasets
were built. Therefore, such an experience-driven method is
not suitable for many kinds of drugs, i.e. drugs for treating
HIV or cancer. These drugs have a relatively narrow effective
therapeutic range for the value of drug concentration in
blood. Since this value after the same administrated dose
to diverse patients differs due to inter- and intra- patients’
variability, it may result in under- or over-dosing patients. If
under-dosed, patients may have a suboptimal response to the
drug treatment, while overdosing may expose them to a risk
of toxicity.
Therapeutic Drug Monitoring (TDM) [1] is an approach
aimed at controlling the drug concentration in a patient’s
blood over time by performing several realtime measure-
ments to further adjust the dose, which we call an a posteriori
adaptation. TDM, however, has several disadvantages: it is
expensive, time-consuming (it may take a day to obtain one
measurement value) and requires an invasive measurement
of an individual drug concentration. Therefore, a novel
approach that can overcome these drawbacks, gives relatively
accurate predictions of drug concentrations and allows cali-
bration of the prediction every time a new measurement of
drug concentration is available is required.
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Recent works [2] have shown a great potential of applying
machine learning methods, i.e. SVMs [3], to predict the
drug concentrations in blood. Compared with the tradi-
tional analytical Pharmacokinetic (PK) method [4], SVM
algorithm has several advantages: it is able to process the
binary/Boolean value inputs and allows us to easily add or
remove features from the set. In [2] it is shown that the SVM
algorithm gives a similar prediction accuracy to the one ob-
tained by using the PK method. In addition, the influence of
different patients’ features on the accuracy of predicting the
drug concentrations is also illustrated. In [5] an extension of
the prediction algorithm by combining the RANdom SAmple
Consensus (RANSAC) algorithm with SVM was proposed.
This extension has improved the prediction accuracy by
about 40%. A Drug Administration Decision Support System
(DADSS) [6] based on this RANSAC-SVM algorithm has
also been proposed. However, all these methods are able
to preform only a point-wise drug concentration predic-
tion and have no knowledge about the dependency among
all predicted values for one patient with fixed parameters.
Therefore, every time a new measured concentration value
is available, it must be added to the initial database and the
whole relearning and predicting process must be applied.
It is computationally heavy, especially if we need to have
complete information about the drug disposition over time.
Solving similar engineering problems [7] uses regression
analysis and [8] proposes a combination rule of evidence
theory. However, these methods do not consider a large
number of features nor future data adaptation.
In this paper, to utilize the advantages of the two, we
present a novel method that combines the SVM algorithm
and an analytical model which describes the DCT curve
derived using a curve fitting process. The parameter library of
the basis functions used for curve interpolation are computed
using the RANSAC algorithm previously applied in [5] to
separate inliers and outliers from a set of (noisy) data. Using
this method, we are able to process as many features as pos-
sible, consider binary inputs, visualize the data represented
in a form of personalized DCT curve for each patient, and
adjust it structurally to make it more personalized with a
given measured concentration value. Moreover, based on the
SVM and RANSAC algorithm, it is also less computationally
expensive and more precise (36% more accurate) than the
PK method [4]. We can further extend the DCT curve from
the single dose regimen to multiple-dose by calibrating each
subsequent computed curve with the value of the residual
drug concentration after previous intake.
The paper is organized as follows: Section II discusses
the background information of a specific drug imatinib
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Fig. 1. Flow of Applying Support Vector Machine Algorithms in Building the Drug Concentration Curves. First row: point-wise concentration value
prediction approach; second row: parameterized Support Vector Machine approach.
considered in this work. Section III describes the proposed
parameterized SVM approach, the curve-adjusting method
and the extension from the single dose regimen to the
multiple dose one. Section IV gives a brief conclusion.
II. BACKGROUND INFORMATION
Imatinib [4], a drug used to treat chronic myeloid leukemia
and gastrointestinal stromal tumors, is the drug considered in
this paper. Until now, only a trough’s therapeutic range of this
drug has been proposed and is presently being validated in
a randomized clinical study in leukemia patients (I-COME;
ISRCTN31181395). Relying on the data presented in [4],
[1] we assume that the trough range has a lower bound at
750µg/L and upper bound at 1500µg/L. The training data
used in this paper includes 54 patients and 252 samples in
total, while the testing data contains 65 patients presenting
gastrointestinal stromal tumors with 209 samples. The set of
input features of patient profile data includes: Gender, Age,
Body Weight, and Type of pathology.
In the current clinical practice, a standard prescription of
400mg dose every 24 hours is administrated to patients in the
chronic phase. Therefore, the trough concentration value is
considered to be measured at 24h (supposing the initial dose
is taken at the time point 0h). In the TDM procedure [9], a
blood sample is taken and the drug concentration in blood
is analyzed several hours after the patient takes a dose.
If the analysis result shows a tendency that the trough
concentration value will exceed the upper bound of the
therapeutic range (1500µg/L), the clinician then reduces the
dose for the patient, and vice versa.
As mentioned in Section I, in [2] we proposed to use
the SVM algorithm to predict the drug concentrations at
any time point taking into account the patients’ personal
features. Compared to TDM, it is a fast, non-invasive and
less expensive method. It is able to give a personalized
amount and interval for the initial dose according to the
therapeutic range of the trough concentration [6]. However,
multiple computations can only resemble the form of the
DCT curve, as illustrated in the first row of Figure 1. This
point-wise prediction approach does not capture the structure
information of the DCT curve itself, hence causing difficul-
ties in adjusting the curve, i.e. when measured concentration
values are available. Further in this paper we describe a
parameterized SVM (ParaSVM) approach which, based on
SVM, also gives the structural information of the DCT curve,
including a curve adjusting method and the construction of
the DCT curve after multiple doses.
III. ALGORITHMS
This section mainly discusses the methods used to realize
the second row of Fig. 1. Unlike applying the SVM algorithm
to predict the concentration values directly after removing
the outliers using the RANSAC algorithm as shown in the
first row, here we first utilize the RANSAC algorithm to
compute the parameter database, or parameter library (III-A),
then apply a parameterized SVM to predict the parameters
used to construct the DCT curve for each patient based
on their personal features (III-B), further adjust the curve
parameters to better illustrate the concentration variation with
one measured concentration value, or a posteriori adaption,
(III-C), and finally construct the DCT curves for multiple-
dose cases. The algorithms proposed in this section are all
developed for the drug imatinib; however, the methods can
be applied to any other drug concentration analysis.
A. Parameter Library
To apply the SVM algorithm, we need to have a set
of training data being the library, which contains training
inputs (patients’ features) and training outputs (DCT curve
parameters). This library is built using the RANSAC algo-
rithm [10], which was originally used to separate inliers
and outliers from a set of (noisy) data with respect to
given basis functions. As presented in [5], the algorithm is
randomly selecting a very small subset of the given input
data, computes the parameters (or weights) of each basis
function considering the small subset, and then determines
the inliers and outliers for the rest of the data with a given
distance value (threshold).
Here, instead of separating inliers and outliers, the
RANSAC algorithm is applied to compute the parameters of
the basis functions for each patient. To remove the outliers
and keep enough data samples to build the subset at the same
time, for each patient we take into account all his/her samples
in addition to the randomly-selected samples from the rest
of the patients to build the subset. We use the common basis
functions β j = {t−2, log(t),1−e−t}, respecting the shape of
DCT curve obtained from the PK method [4], where t stands
for time [5]. Therefore, the target is to obtain the parameters
y for the weights of β :
fconcentration = y ·β =
[
y1 y2 y3
]β 1β 2
β 3
 (1)
These parameters {y1,y2,y3} together with patients’ features
form the Parameter Library being used as the training data.
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B. Parameterized SVM (ParaSVM)
Instead of predicting the drug concentration values [2], we
applythe SVM algorithm to learn the mathematic relationship
between the parameters of the basis functions extracted in
Section III-A and then predict the parameter values of the
DCT curve for a new patient in the testing dataset. To build
one DCT curve in our case, three parameters are required.
Therefore, the main difference is the inclusion of minimizing
the objective function which considers a combined difference
between the predicted parameter values and the ones in the
parameter library (training dataset).
In the case of modeling N patient samples, the form of
patient samples becomes (xi,y1i , · · · ,y ji , · · · ,yNPi ), where i is
the ID of a sample i ∈ {1,2 · · · ,N}, xi represents the feature
values of i-th patient, y ji denotes the j-th parameter value
of this patient, and NP is the number of parameters. The
goal is to find NP linear functions f j(x) = w j ·φ j(x)+b j to
describe the relationship in between the dataset points and
to estimate the parameter value y ji according to a new input
dataset. Based on [2], we minimize the following modified
objective function:
min
w,b
1
2
||w||2+C0
NP
∑
j=1
N
∑
i=1
[y ji −w j ·φ j(xi)−b j]2︸ ︷︷ ︸
H
, (2)
where H takes into account the combined difference of all
three predicted values plus the ones in the parameter library.
Note that this objective function has Root of Sum of Square
(RSS) fitting error and a regularization term, which is also a
standard procedure for the training of Multi Layer Perceptron
(MLP) and is related to ridge regression [11], [12]. Applying
Lagrangian analysis to solve the optimization problem of
the objective function, we obtain w as: w j = ∑Ni=1α
j
i φ
j(xi),
which gives a linear system together with Equation(2):[
K j+ 1C0 I 1
1T 0
][
α j
b j
]
=
[
y j
0
]
(3)
where each entry of the kernel matrix K j is defined to
be K jab = φ
j(xa)Tφ j(xb). A Gaussian Kernel is applied in
a similar way as in [2]. Therefore, the prediction func-
tion for the DCT curve parameters becomes: Para j(x) =
∑Ni=1αiK j(xi,x) + b j. Table I compares the prediction ac-
curacy in absolute differences of the proposed ParaSVM,
RANSAC-SVM[5] (RSVM) and the PK method towards the
measured concentration values. The percentages indicate the
improvement of the methods when comparing with the PK
one. It shows that ParaSVM improves the average prediction
accuracy by about 36.13% to PK method, which is 5%
less accurate than the performance of RSVM. However,
ParaSVM further provides a way of adapting the DCT curve
structurally as discussed in the following subsections.
C. The a posteriori Adaptation
In an a posteriori dose adaptation, we refine the predicted
DCT curve computed by ParaSVM. It is done by calibrating
the current DCT curve using one or several measured data
TABLE I
COMPARISONS OF PK METHOD, RANSAC-SVM (RSVM), AND
PARASVM IN MEAN AND STD DIFFERENCES TO MEASURED VALUES.
PK RSVM [5] ParaSVM
Mean [µg/L] 421.42 247.61 41.24% 269.16 36.13%
STD [µg/L] 384.55 211.31 45.05% 259.82 32.44%
(a)
(b)
Fig. 2. Two Examples of Parametrically Refined Drug Concentration to
Time Curves for the Drug imatinib. Blue curve: DCT curve computed by the
ParaSVM approach; Red curve: DCT curve adjusted with one measurement;
Crosses: measured concentrations; Circles: predicted concentration based
on the DCT curve. Dotted black circle: measured point chosen for curve
refinement. X-axis: time [h], Y-axis: concentration value [µg/L]
point under certain constraints. Taking into account that these
measurements are done for the same patient, the calibration
makes the DCT curve more personalized with each new mea-
surement. The same DCT curve adjustment approach is also
applied to build the concentration curve for multiple dose
regimens using the computed trough concentration value
from the previous cycle (computation) as a measurement.
Once there is a new measurement we first predict the
basis function’s parameters using ParaSVM and then search
within a certain radius δD around each parameter value with
a step δd to find the best set of parameters that satisfies the
following conditions:
• The modified DCT curve has to pass through the given
measured concentration value;
• After giving the dose, the concentration value should
increase with time: ∂ fconcentration∂ t |t=0 > 0;
• After several hours, the concentration value reaches the
peak value and starts to decrease: ∂ fconcentration∂ t |t=Tp < 0,
where Tp is a time point after the peak value, i.e. we
set it as Tp = 24h.
• Considering the trough value or residual value, from
the previous dose, the difference between the starting
value of DCT curve (t = 0) and the ending one (t =
24h, since imatinib is usually administrated once a day),
should be within a certain range (R), i.e. < 50µg/L:
| f t=0concentration− f t=24concentration|< R.
• The DCT curve whose shape is the closest to the
curve previously predicted by ParaSVM will be chosen:
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Fig. 3. Example of Multiple dose Estimation for the Drug Concentration
to Time Curve Over 10 Days of Drug imatinib. X-axis: time [h], Y-axis:
concentration value [µg/L]
mingr ∑ j=0,··· ,Ns(g
t= j
r −gt= j)2, where gt= j stands for the
concentration value at time j and gt= jr is the one in the
refined curve. The set of parameters y corresponding to
the best gr are selected.
Fig. 2 shows two examples of parametrically refined DCT
curves for the drug imatinib. The upper curve (blue) in
Fig. 2(a) and the lower curve in Fig. 2(b) are computed by
ParaSVM, on which the points (blue) are the drug concen-
trations that correspond to the measuring time in the testing
database. Similarly, the lower curve (red) in Fig. 2(a) and the
upper curve (red) in Fig. 2(b) are curves adjusted with one
measurement meeting the above constraints, on which the
points (red) are the concentrations after the adjustment. The
crosses are the measured concentration values in the testing
database. The black dotted circle in both figures represent
the measured point chosen for the adjustment process. From
these figures one can see, the proposed ParaSVM approach
is able to minimize the difference between the predicted
concentration values and the measured ones.
In the example of Fig. 2(a), the refined DCT curve with
respect to the measurement in the dotted circle improves the
prediction accuracy for the other two measurements. In Fig.
2(b), the refined DCT curve also goes through the second
measured value, while the original predicted curve predicts
the concentrations to be smaller than the measured ones.
D. Multiple Dose Estimation
Knowing how the concentration varies with time after
multiple doses is important to clinicians and patients in order
to monitor a long term therapeutic procedure. Fig. 3 shows
an example of estimating the drug concentration over 10
days based on ParaSVM taking into account the residual
drug concentration from the previous day. In an a posteriori
case, after we adjust the concentration curve with a given
measurement, the multi-dose DCT curve can be obtained by
computing over days the updated one-dose DCT curve. As
the drug sometimes takes more than 24 hours to be clear from
the human body, we also consider the residual concentration
values from the previous dose(s).
The DCT curve for multiple doses makes it visually easy
to obtain the peak and trough concentration values and to
check whether they are within the therapeutic ranges or not.
As shown in Fig. 3, the residual concentration affects both
the peak and the trough concentration values, especially at
the beginning of the treatment.
IV. CONCLUSIONS
In this paper, we have presented a novel approach,
ParaSVM, that complements the SVM method with an
analytical model , which allows us to consider various patient
features, build the DCT curve, adjust it with occasional
real TDM measurements, and construct the multi-dose curve
afterwards. The main contribution of this work is the com-
bination of an implicit machine learning algorithm with an
explicit analytical model. The ParaSVM model shows slight
reduction in the prediction accuracy (5%) compared with
SVM approach, however, it is still more than 35% accurate
than the PK method.
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